AU2018338451A1 - Immunoassays for detection of RAN proteins - Google Patents

Immunoassays for detection of RAN proteins Download PDF

Info

Publication number
AU2018338451A1
AU2018338451A1 AU2018338451A AU2018338451A AU2018338451A1 AU 2018338451 A1 AU2018338451 A1 AU 2018338451A1 AU 2018338451 A AU2018338451 A AU 2018338451A AU 2018338451 A AU2018338451 A AU 2018338451A AU 2018338451 A1 AU2018338451 A1 AU 2018338451A1
Authority
AU
Australia
Prior art keywords
ran
poly
subject
antibody
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018338451A
Other languages
English (en)
Inventor
Lien Nguyen
Laura Ranum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of AU2018338451A1 publication Critical patent/AU2018338451A1/en
Priority to AU2024219412A priority Critical patent/AU2024219412A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/30—Electrochemically active labels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Plasma & Fusion (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2018338451A 2017-09-25 2018-09-25 Immunoassays for detection of RAN proteins Abandoned AU2018338451A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024219412A AU2024219412A1 (en) 2017-09-25 2024-09-04 Immunoassays for detection of ran proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563009P 2017-09-25 2017-09-25
US62/563,009 2017-09-25
PCT/US2018/052745 WO2019060918A1 (en) 2017-09-25 2018-09-25 IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024219412A Division AU2024219412A1 (en) 2017-09-25 2024-09-04 Immunoassays for detection of ran proteins

Publications (1)

Publication Number Publication Date
AU2018338451A1 true AU2018338451A1 (en) 2020-04-02

Family

ID=65811531

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018338451A Abandoned AU2018338451A1 (en) 2017-09-25 2018-09-25 Immunoassays for detection of RAN proteins
AU2024219412A Pending AU2024219412A1 (en) 2017-09-25 2024-09-04 Immunoassays for detection of ran proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024219412A Pending AU2024219412A1 (en) 2017-09-25 2024-09-04 Immunoassays for detection of ran proteins

Country Status (6)

Country Link
US (1) US12504380B2 (OSRAM)
EP (1) EP3688020A4 (OSRAM)
JP (2) JP2020535448A (OSRAM)
AU (2) AU2018338451A1 (OSRAM)
CA (1) CA3075908A1 (OSRAM)
WO (1) WO2019060918A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904960A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
CA3019847A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
AU2018255293B2 (en) 2017-04-17 2024-03-07 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2a-P pathways
AU2018338451A1 (en) 2017-09-25 2020-04-02 University Of Florida Research Foundation, Incorporated Immunoassays for detection of RAN proteins
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
WO2021007110A1 (en) * 2019-07-05 2021-01-14 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
CA3154741A1 (en) * 2019-09-20 2021-03-25 University Of Florida Research Foundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
WO2021072187A2 (en) * 2019-10-10 2021-04-15 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders
US20250164489A1 (en) * 2022-02-28 2025-05-22 University Of Florida Research Foundation, Incorporated Ran proteins in sporadic amyotrophic lateral sclerosis

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
BR9608278A (pt) 1995-04-11 1999-10-13 Merck & Co Inc Processo para produzir um intermediário de dipeptìdeo de um composto à base de dipeptìdeo
NZ337703A (en) 1997-03-05 2001-05-25 Univ Washington A screening method to identify agents that selectively inhibit Hepatitis C virus replication in viruses that contain an ISDR region
JP2002513295A (ja) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド １２３種類のヒト分泌タンパク質
WO1999011667A1 (en) 1997-08-29 1999-03-11 Innogenetics N.V. METHYLATED, SmD HOMOLOGOUS PEPTIDES, REACTIVE WITH THE ANTIBODIES FROM SERA OF LIVING BEINGS AFFECTED WITH SYSTEMIC LUPUS ERYTHEMATOSUS
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1278854A2 (en) 2000-04-21 2003-01-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
AU2002249787A1 (en) 2000-10-25 2002-08-19 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
EP1349934A2 (en) 2000-11-20 2003-10-08 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US7528227B2 (en) 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7393642B2 (en) 2003-07-17 2008-07-01 Chicago Community Foundation Methods and primers for diagnosing idiopathic congenital central hypoventilation syndrome
ES2874298T3 (es) 2003-09-30 2021-11-04 Univ Pennsylvania Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos
WO2005089164A2 (en) 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
JP4878551B2 (ja) 2004-04-08 2012-02-15 貞和 相磯 運動ニューロン疾患治療薬
EP1794593A2 (en) * 2004-09-21 2007-06-13 Matritech, Inc. Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
AU2006210973A1 (en) 2005-01-31 2006-08-10 University Of Iowa Research Foundation Nucleic acid silencing of Huntington's Disease gene
US20090074721A1 (en) 2005-06-06 2009-03-19 Vgx Pharmaceuticals, Inc. Methods for treating viral infection with oral or injectibel drug solution
JP2009515885A (ja) 2005-11-11 2009-04-16 オーロゲン インコーポレイテッド 組織の収縮又は萎縮に関連する成人中枢神経系の疾病又は障害をインスリン投与によって治療する方法
ES2453374T3 (es) * 2006-09-20 2014-04-07 The Queen's University Of Belfast Método para determinar si una célula tumoral presenta potencial invasivo y/o metastásico, y agentes moduladores de la transformación maligna
US20080188457A1 (en) 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
US20090148866A1 (en) * 2007-05-18 2009-06-11 Abbott Laboratories Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase
WO2008151833A2 (en) 2007-06-13 2008-12-18 Hochschule Mannheim Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
US20090143418A1 (en) 2007-11-30 2009-06-04 The Regents Of The University Of Michigan Compositions and Methods for Preventing and Treating Hair Growth Cycle-Related Conditions
GB0809821D0 (en) 2008-05-30 2008-07-09 Univ Aberdeen Treatment and diagnosis of behavioural disorders
TW201034684A (en) 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
CA2757354A1 (en) 2009-04-02 2010-10-07 Laura P.W. Ranum Nucleotide repeat expansion-associated polypeptides and uses thereof
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
CA2762351A1 (en) 2009-05-18 2010-11-25 Ottawa Hospital Research Institute Treatment of muscle disease characterized by insulin resistance
US20120220534A1 (en) 2009-09-03 2012-08-30 University Of Tennessee Research Foundation Biomarker for neurodegeneration in neurological disease
KR101133243B1 (ko) 2009-10-29 2012-04-06 국립암센터 암의 진단 및 치료를 위한 ｅＩＦ３ｍ의 용도
WO2011121109A1 (en) 2010-04-02 2011-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
LT3892295T (lt) 2011-05-24 2023-07-10 BioNTech SE Individualizuotos vakcinos nuo vėžio
EP2751284B1 (en) 2011-08-31 2017-01-11 The University Of Manchester Method for diagnosing a neurodegenerative disease.
PH12014500940A1 (en) 2011-10-28 2019-06-26 Biogen Int Neuroscience Gmbh Tdp-43 specific binding molecules
HK1203566A1 (zh) 2012-02-29 2015-10-30 桑格摩生物科学股份有限公司 治療亨廷頓氏病的方法和組合物
KR101417272B1 (ko) 2012-05-15 2014-07-14 경상대학교산학협력단 메트포민 및/또는 타이모퀴논을 포함하는 임신중 알코올 노출에 의한 신경질환 치료 또는 예방용 약학적 조성물
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
RS59283B1 (sr) 2013-01-22 2019-10-31 Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V Proteini sa dipeptidnim ponovkom kao terapeutsko ciljno mesto kod neurodegenerativnih bolesti sa ekspanzijom heksanukleotidnog ponovka
WO2014114303A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
WO2014116865A1 (en) 2013-01-24 2014-07-31 Mayo Foundation For Medical Education And Research Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
CA2904960A1 (en) * 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
AU2014233520B2 (en) 2013-03-15 2019-02-21 The Regents Of The University Of California Modulators of the eIF2alpha pathway
US10006049B2 (en) 2013-05-16 2018-06-26 University Of Florida Research Foundation, Incorporated Hairpin mRNA elements and methods for the regulation of protein translation
EP2837390A1 (en) 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders
WO2016025692A1 (en) * 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
JP6508996B2 (ja) 2015-03-24 2019-05-08 東ソー株式会社 β−ＡＮＰによる心不全の検出方法
WO2016168143A1 (en) 2015-04-14 2016-10-20 Bristol-Myers Squibb Company IMMUNOASSAY FOR SOLUBLE PROGRAMMED DEATH-1 (sPD-1) PROTEIN
WO2016191241A1 (en) 2015-05-27 2016-12-01 Mmc & Company Llc Dual target mitochondrial impinging pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
DK3356827T3 (da) 2015-10-02 2024-01-08 Univ Wuerzburg J Maximilians Gdf-15 som en diagnostisk markør til forudsigelse af det kliniske resultat af en behandling med immun-checkpoint-blokkere
CA3019847A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
AU2017313823A1 (en) 2016-08-18 2019-02-28 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides
AU2018255293B2 (en) 2017-04-17 2024-03-07 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2a-P pathways
AU2018338451A1 (en) 2017-09-25 2020-04-02 University Of Florida Research Foundation, Incorporated Immunoassays for detection of RAN proteins
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
EP3710836A4 (en) 2017-11-16 2021-10-27 Brainbox Solutions, Inc. PROTEIN BIOMARKER INDICATORS OF NEUROLOGICAL INJURY AND / OR DISEASE AND METHOD OF USE THEREOF
EP3962518A1 (en) 2019-05-02 2022-03-09 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Immunogen for preventing or treating familial frontotemporal dementia (ftd) and/or amyotrophic lateral sclerosis (als)
WO2021007110A1 (en) 2019-07-05 2021-01-14 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
CA3154741A1 (en) 2019-09-20 2021-03-25 University Of Florida Research Foundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
AU2020354387A1 (en) 2019-09-23 2022-04-07 University Of Florida Research Foundation, Incorporated Vaccine therapy for ran protein diseases
WO2021072187A2 (en) 2019-10-10 2021-04-15 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders
US20230304088A1 (en) 2020-05-15 2023-09-28 University Of Florida Research Foundation, Incorporated Compositions and methods of detection of pre-symptomatic als
WO2023102111A1 (en) 2021-12-01 2023-06-08 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies
US20250164489A1 (en) 2022-02-28 2025-05-22 University Of Florida Research Foundation, Incorporated Ran proteins in sporadic amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
WO2019060918A8 (en) 2019-04-18
EP3688020A4 (en) 2021-07-14
AU2024219412A1 (en) 2024-09-26
JP2023174663A (ja) 2023-12-08
CA3075908A1 (en) 2019-03-28
JP2020535448A (ja) 2020-12-03
EP3688020A1 (en) 2020-08-05
US20200232925A1 (en) 2020-07-23
WO2019060918A1 (en) 2019-03-28
US12504380B2 (en) 2025-12-23

Similar Documents

Publication Publication Date Title
US12504380B2 (en) Immunoassays for detection of ran proteins
US20120065148A1 (en) Phosphodiesterase 4d7 as prostate cancer marker
JP2011501741A (ja) がんの診断および治療のためのｔａｚ／ｗｗｔｒ１
US20240069039A1 (en) Ran proteins as biomarkers in cag/ctg expansion disorders
WO2014208645A1 (ja) そう痒を伴う疾患に罹患した患者のｉｌ－３１アンタゴニストによる治療に対する応答を予測する方法
JP2005510251A5 (OSRAM)
JP6240919B2 (ja) 加齢または筋萎縮の診断用バイオマーカー
US20160139149A1 (en) Chi3l1 for the detection and treatment of nonalcoholic steatohepatitis
KR20230081950A (ko) 갑상선 안병증의 진단을 위한 바이오마커 및 이의 용도
JP2006520588A (ja) 治療薬、予防薬、および診断薬
KR102583540B1 (ko) 퇴행성 뇌질환에서 zbtb16의 용도
CN111630185A (zh) 包含pmvk作为活性成分的用于诊断耐放射癌症或预测放射疗法预后的生物标志物组合物
JP2014095643A (ja) 炎症性疾患治療薬のスクリーニング方法、並びに炎症性疾患の治療及び検査
EP2791686B1 (en) Tenascin-c and use thereof in rheumatoid arthritis
JP2016104716A (ja) 膵臓癌治療用のｃｄ９５シグナル伝達阻害化合物
US20240210407A1 (en) Compositions and methods for detecting and treating pathological fibroblast cells
CN111440870A (zh) CircZCCHC11及其翻译的肽段在肿瘤生长和转移预测、预后评估和治疗中的应用
US20240280590A1 (en) Compositions and methods for facioscapulohumeral muscular dystrophy biomarker detection
CA2801162A1 (en) Diagnostic, screening and therapeutic applications of ocab-based tools
US7674578B2 (en) Methods of using sIP-10 to assess HCV clearance and/or response to interferon therapy
JP2025077049A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
JP2012093351A (ja) 腎障害の新規マーカー
WO2023041805A1 (en) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
CN117794584A (zh) 包含msh2或msh6抑制剂作为有效成分的用于预防或治疗癌症的组合物
JPWO2006035702A1 (ja) Ｃペプチド特異的結合分子及びその用途

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted